Ulf Boemer
Bayer Schering Pharma AG
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ulf Boemer.
Acta Crystallographica Section D-biological Crystallography | 2011
Michèle N. Schulz; Jörg Fanghänel; Martina Schäfer; Volker Badock; Hans Briem; Ulf Boemer; Duy Nguyen; Manfred Husemann; Roman Hillig
A crystallographic fragment screen was carried out to identify starting points for the development of inhibitors of protein kinase Pim-1, a potential target for tumour therapy. All fragment hits identified via soaking in this study turned out to bind to the unusually hydrophobic pocket at the hinge region. The most potent fragments, two cinnamic acid derivatives (with a best IC(50) of 130 µM), additionally form a well defined hydrogen bond. The balance between hydrophobic and polar interactions makes these molecules good starting points for further optimization. Pim-2 inhibitors from a recently reported high-throughput screening campaign also feature a cinnamic acid moiety. Two of these Pim-2 inhibitors were synthesized, their potencies against Pim-1 were determined and their cocrystal structures were elucidated in order to determine to what degree the binding modes identified by fragment screening are conserved in optimized inhibitors. The structures show that the cinnamic acid moieties indeed adopt the same binding mode. Fragment screening thus correctly identified binding modes which are maintained when fragments are grown into larger and higher affinity inhibitors. The high-throughput screening-derived compound (E)-3-{3-[6-(4-aminocyclohexylamino)-pyrazin-2-yl]phenyl}acrylic acid (compound 1) is the most potent inhibitor of the cinnamic acid series for which the three-dimensional binding mode is known (IC(50) = 17 nM, K(d) = 28 nM). The structure reveals the molecular basis for the large gain in potency between the initial fragment hit and this optimized inhibitor.
Archive | 2003
Wolfgang Schwede; Volker Schulze; Knut Eis; Bernd Buchmann; Hans Briem; Gerhard Siemeister; Ulf Boemer; Karsten Parczyk
Archive | 2006
Ulrich Lücking; Duy Nguyen; Arne Von Bonin; Oliver Von Ahsen; Martin Krüger; Hans Briem; Georg Kettschau; Olaf Prien; Anne Mengel; Krolikiewicz Konrad; Ulf Boemer; Ulrich Bothe; Ingo Hartung
Archive | 2007
Ingo Hartung; Georg Kettschau; Hans Briem; Karl-Heinz Thierauch; Ulrich Luecking; Ulf Boemer; Martin Krueger
Cancer Research | 2018
Martin Lange; Antje Margret Wengner; Ulrich Bothe; Ulf Boemer; Reinhard Nubbemeyer; Holger Siebeneicher; Holger Steuber; Judith Guenther; Lisette Potze; Nicole Schmidt; Oliver Politz; Wolf-Dietrich Doecke; Eleni Lagkadinou; Thomas Matthias Zollner; Franz von Nussbaum; Dominik Mumberg; Andreas Steinmeyer; Michael Brands; Karl Ziegelbauer
Archive | 2008
Hans Briem; Ingo Hartung; Georg Kettschau; Stuart Ince; Karl-Heinz Thierauch; Ulf Boemer
Archive | 2008
Hartmut Schirok; Ying Li-Sommer; Michael Brands; Mario Lobell; Adrian Tersteegen; Herbert M. Himmel; Karl-Heinz Schlemmer; Dieter Lang; Kirstin Petersen; Matthias Renz; Dominik Mumberg; Jens Hoffmann; Gerhard Siemeister; Ulf Boemer
Archive | 2008
Ingo Hartung; Hans Briem; Georg Kettschau; Karl-Heinz Thierauch; Ulf Boemer
Archive | 2007
Ulf Boemer; Ulrich Bothe; Gudith Guenther; Duy Nguyen; Bonin Arne Von
Archive | 2007
Ulf Boemer; Ulrich Bothe; Judith Guenther; Duy Nguyen; Bonin Arne Von